Anti-CES2 monoclonal antibody, clone FQS25967

In this research, the toxicological effect of untreated wastewater from of ethyl alcohol industry was evaluated on the zebrafish (Danio rerio) under experimental conditions. Fish were treated with zero, half, one and two percent of sewage effluent for 21 days. Toxic effects were monitored in liver by determining biochemical indicators, oxidative stress biomarkers, and the expression of genes involved in the detoxification. Results showed that Sod1, Gstp-1a, Gpx1a gene expressions were significantly increased in the hepatocytes after 21 days at 2.0% sewage exposure. Sewage exposure also significantly increased Gsr, Ces2 and Cyp1a, Mt1 and Mt2 gene expression in the hepatocytes of zebrafish as compared to the reference group (P < 0.01). Total cellular antioxidants, malondialdehyde (MDA) levels, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP) activities in fish exposed to 1 and 2% of sewage were significantly higher than the control group (P < 0.01), whereas alanine aminotransferase (ALT) was only increased in fish exposed to 2% sewage (P < 0.01). A significant decrease in gamma-glutamyl-transferase (GGT) activity in fish exposed to 2% effluent was found (P < 0.01). Catalase (CAT) activity was increased in zebrafish exposed to all concentrations of effluent. The transcriptional analysis of the detoxification-related genes and the changes in the biochemical indicators evidenced that drainage of sewage effluents from the ethyl alcohol company is a serious threat to the health of aquatic animals in the Khorram-Rood River. These results will contribute to further study on the impact of sewage effluents of the alcohol industry on aquatic organisms. (C) 2020 Elsevier Ltd. All rights reserved.

Purpose: The purpose was to explore the relationships between irinotecan disposition and allelic variants of genes coding for adenosine triphosphate binding cassette transporters and enzymes of putative relevance for irinotecan. Experimental Design: Irinotecan was administered to 65 cancer patients as a 90-min infusion (dose, 200-350 mg/m(2)), and pharmacokinetic data were obtained during the first cycle. All patients were genotyped for variants in genes encoding MDR1 P-glycoprotein (ABCB1), multidrug resistance-associated proteins MRP-1- (ABCC1) and MRP-2 (canalicular multispecific organic anion transporter; ABCC2), breast cancer resistance protein (ABCG2), carboxylesterases (CES1, CES2), cytochrome P450 isozymes (CYP3A4, CYP3A5), UDP glucuronosyltransferase (UGT1A1), and a DNA-repair enzyme (XRCC1), which was included as a nonmechanistic control. Results: Eighteen genetic variants were found in nine genes of putative importance for irinotecan disposition. The homozygous T allele of the ABCB1 1236C>T polymorphism was associated with significantly increased exposure to irinotecan (P = 0.038) and its active metabolite SN-38 (P = 0.031). Pharmacokinetic parameters were not related to any of the other multiple variant genotypes, possibly because of the low allele frequency. The extent of SN-38 glucuronidation was slightly impaired in homozygous variants of UGT1A1*28, although differences were not statistically significant (P = 0.22). Conclusions: It is concluded that genotyping for ABCB1 1236C>T may be one of the factors assisting with dose optimization of irinotecan chemotherapy in cancer patients. Additional investigation is required to confirm these findings in a larger population and to assess relationships between irinotecan disposition and the rare variant genotypes, especially in other ethnic groups.